Bo Young Kim1, Nayeon Choi2, Sun Wook Kim3, Han-Sin Jeong4, Man Ki Chung5, Young- Ik Son6. 1. Department of Otorhinolaryngology-Head and Neck Surgery, Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, Republic of Korea. 2. Graduate School of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 3. Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 4. Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 5. Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. chungmk@skku.edu. 6. Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. yison@skku.edu.
Abstract
PURPOSE: This study aimed to evaluate the role of prophylactic ipsilateral central neck dissection (pCND) in patients with clinically node-negative (cN0) papillary thyroid microcarcinoma (PTMC). METHODS: In this randomized control trial, a total of 164 consecutive patients were enrolled. By double-blinded randomization protocol, patients were allocated into hemithyroidectomy with pCND (n = 82) or without pCND (n = 82). With intention-to-treat analysis, post-surgical pathological and clinical course, surgery-related complications, causes and clinical course of protocol-violated cases and 5-year recurrence-free survival were compared. RESULTS: Operation time, hospital stay, and post-surgical complication were not significantly different between the two groups. In the pCND (+) group, occult lymph node metastasis rate was 50.0%, and lymph node ratio (metastatic/harvested lymph nodes) was 45.2%. Ten patients in the pCND (+) group had converted to undergo onsite or staged completion total thyroidectomy due to the presence of metastatic central lymph nodes and/or positive resection margin. Until last follow-up (mean 73.4 months), one regional recurrence developed in the pCND (-) group, and three regional recurrences occurred in the pCND (+) group. Five-year recurrence-free survival was similar between the two groups. CONCLUSION: Although ipsilateral pCND could clear occult lymph node metastasis in the central compartment, it failed to provide any oncological benefit for cN0 PTMC patients.
PURPOSE: This study aimed to evaluate the role of prophylactic ipsilateral central neck dissection (pCND) in patients with clinically node-negative (cN0) papillary thyroid microcarcinoma (PTMC). METHODS: In this randomized control trial, a total of 164 consecutive patients were enrolled. By double-blinded randomization protocol, patients were allocated into hemithyroidectomy with pCND (n = 82) or without pCND (n = 82). With intention-to-treat analysis, post-surgical pathological and clinical course, surgery-related complications, causes and clinical course of protocol-violated cases and 5-year recurrence-free survival were compared. RESULTS: Operation time, hospital stay, and post-surgical complication were not significantly different between the two groups. In the pCND (+) group, occult lymph node metastasis rate was 50.0%, and lymph node ratio (metastatic/harvested lymph nodes) was 45.2%. Ten patients in the pCND (+) group had converted to undergo onsite or staged completion total thyroidectomy due to the presence of metastatic central lymph nodes and/or positive resection margin. Until last follow-up (mean 73.4 months), one regional recurrence developed in the pCND (-) group, and three regional recurrences occurred in the pCND (+) group. Five-year recurrence-free survival was similar between the two groups. CONCLUSION: Although ipsilateral pCND could clear occult lymph node metastasis in the central compartment, it failed to provide any oncological benefit for cN0 PTMC patients.
Authors: Suyeon Park; Min Ji Jeon; Hye-Seon Oh; Yu-Mi Lee; Tae-Yon Sung; Minkyu Han; Ji Min Han; Tae Yong Kim; Ki-Wook Chung; Won Bae Kim; Young Kee Shong; Won Gu Kim Journal: Thyroid Date: 2018-07-24 Impact factor: 6.568
Authors: D Viola; G Materazzi; L Valerio; E Molinaro; L Agate; P Faviana; V Seccia; E Sensi; C Romei; P Piaggi; L Torregrossa; S Sellari-Franceschini; F Basolo; P Vitti; R Elisei; P Miccoli Journal: J Clin Endocrinol Metab Date: 2015-01-15 Impact factor: 5.958
Authors: Sophie Leboulleux; Carole Rubino; Eric Baudin; Bernard Caillou; Dana M Hartl; Jean-Michel Bidart; Jean-Paul Travagli; Martin Schlumberger Journal: J Clin Endocrinol Metab Date: 2005-07-19 Impact factor: 5.958
Authors: Seo Ki Kim; Jung-Woo Woo; Jun Ho Lee; Inhye Park; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim Journal: J Am Coll Surg Date: 2016-02-13 Impact factor: 6.113
Authors: Tracy S Wang; Kevin Cheung; Forough Farrokhyar; Sanziana A Roman; Julie Ann Sosa Journal: Ann Surg Oncol Date: 2013-07-12 Impact factor: 5.344
Authors: Vivian Hsiao; Tyler J Light; Abdullah A Adil; Michael Tao; Alexander S Chiu; Mary Hitchcock; Natalia Arroyo; Sara Fernandes-Taylor; David O Francis Journal: JAMA Otolaryngol Head Neck Surg Date: 2022-06-01 Impact factor: 8.961